Is Mounjaro Covered by Blue Cross Blue Shield? What Your Plan Actually Pays in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Blue Cross Blue Shield coverage for Mounjaro varies by plan tier, state, and whether you have type 2 diabetes or obesity as your diagnosis
• Most BCBS plans cover Mounjaro for type 2 diabetes with prior authorization, but fewer than 40% cover it for weight loss alone as of April 2026
• Copays range from $25 to $1,468 per month depending on formulary tier and whether you qualify for manufacturer savings programs
• If your BCBS plan denies coverage, compounded tirzepatide through FormBlends costs $297 to $399 per month with no prior authorization required

Direct answer (40-60 words)

Blue Cross Blue Shield coverage for Mounjaro depends on your specific plan, state, and diagnosis. Most BCBS plans cover Mounjaro for type 2 diabetes after prior authorization approval, with copays ranging from $25 to $600 per month. Coverage for weight loss without diabetes is less common and typically requires documented BMI over 30 plus comorbidities.

Table of contents

1. The coverage landscape: what changed in 2024-2026
2. How BCBS formulary tiers work and where Mounjaro sits
3. Type 2 diabetes vs obesity: the diagnosis that determines coverage
4. The prior authorization process: what BCBS actually requires
5. State-by-state variations in BCBS Mounjaro coverage
6. What most articles get wrong about "covered" vs "affordable"
7. The real cost breakdown: copays, deductibles, and out-of-pocket maximums
8. Manufacturer savings programs and why they don't work for everyone
9. When BCBS denies coverage: the appeal process that works
10. Compounded tirzepatide as the coverage-independent alternative
11. The decision tree: should you fight for coverage or switch to compounded?
12. FAQ
13. Sources

The coverage landscape: what changed in 2024-2026

Blue Cross Blue Shield is not a single insurance company. It's a federation of 34 independent companies operating under shared branding. Each company sets its own formulary, which means BCBS of Illinois has different Mounjaro coverage than BCBS of North Carolina or Anthem Blue Cross in California.

The coverage landscape shifted dramatically between 2024 and 2026:

2022-2023: Mounjaro was new. Most BCBS plans placed it on specialty tier (tier 4 or 5), requiring prior authorization for type 2 diabetes only. Weight loss was explicitly excluded.

2024: The FDA approved tirzepatide for chronic weight management under the brand name Zepbound. BCBS plans responded inconsistently. Some added Zepbound to formularies with strict criteria. Others excluded all weight-loss GLP-1 medications regardless of brand.

2025: Medicare announced it would not cover GLP-1 medications for weight loss, citing the statutory exclusion for weight-loss drugs. Many commercial BCBS plans followed suit, tightening criteria even for patients with obesity-related comorbidities.

April 2026: The current state. Roughly 65% of BCBS plans cover Mounjaro for type 2 diabetes. Fewer than 40% cover it for weight loss, and those that do require BMI over 30 (or over 27 with comorbidities), prior failure of other weight-loss interventions, and ongoing documentation of weight loss to maintain coverage.

The trend is toward restriction, not expansion. Employer groups are pressuring BCBS plans to exclude or limit GLP-1 coverage due to budget impact. A 2025 analysis by the Peterson-KFF Health System Tracker found that GLP-1 medications accounted for 5% of total drug spending across commercial plans despite representing less than 1% of prescriptions.

How BCBS formulary tiers work and where Mounjaro sits

BCBS plans use a tiered formulary system. The tier determines your copay or coinsurance:

Tier	Drug type	Typical copay structure	Prior authorization required
Tier 1	Preferred generic	$5-$15	Rarely
Tier 2	Non-preferred generic or preferred brand	$25-$50	Sometimes
Tier 3	Non-preferred brand	$50-$100	Often
Tier 4	Specialty (injectable, biologic, high-cost)	20-30% coinsurance ($200-$600)	Always
Tier 5	Specialty non-preferred	30-50% coinsurance ($400-$1,200)	Always

Mounjaro sits on tier 4 or tier 5 in most BCBS plans. The exact tier depends on:

1. Whether your plan has a GLP-1 preferred drug. Some BCBS plans designate Ozempic (semaglutide) as the preferred GLP-1 for diabetes and place Mounjaro on tier 5 as non-preferred. Others treat them equally.
2. Your state. States with pharmacy benefit mandates (like California and New York) sometimes require lower cost-sharing for diabetes medications, which can move Mounjaro to tier 3.
3. Your employer group's negotiations. Large employers can negotiate custom formularies. A Fortune 500 company's BCBS plan may have different Mounjaro placement than a small business plan in the same state.

The tier matters more than the yes/no coverage question. A tier 4 placement with 25% coinsurance on a $1,468 list price means a $367 monthly copay. A tier 5 placement with 40% coinsurance means $587 per month. Both are "covered," but affordability differs.

Type 2 diabetes vs obesity: the diagnosis that determines coverage

The diagnosis code on your prescription determines whether BCBS will cover Mounjaro.

Type 2 diabetes (ICD-10 codes E11.x):

• Coverage rate across BCBS plans: approximately 65% as of April 2026
• Prior authorization approval rate: 70-80% when criteria are met
• Typical criteria: HbA1c above 7.0% despite metformin or other first-line therapy, documented trial of at least one other diabetes medication, no history of medullary thyroid carcinoma or MEN2
• Copay tier: usually tier 4, sometimes tier 3 in states with diabetes drug mandates

Obesity without diabetes (ICD-10 codes E66.x):

• Coverage rate across BCBS plans: approximately 35-40% as of April 2026
• Prior authorization approval rate: 40-50% when criteria are met
• Typical criteria: BMI over 30 (or over 27 with weight-related comorbidities like hypertension, sleep apnea, or dyslipidemia), documented failure of behavioral weight-loss program, ongoing provider supervision, requirement to demonstrate 5% weight loss within first 12 weeks to continue coverage
• Copay tier: usually tier 5 when covered at all

The pattern we see across FormBlends patients who check their BCBS coverage: diabetes diagnosis gets approved 3 times more often than obesity diagnosis, even when the patient has the same BMI and comorbidities. The coverage gap is policy-driven, not clinical.

The prior authorization process: what BCBS actually requires

Prior authorization is the gatekeeper. Even if Mounjaro is on your formulary, you can't fill the prescription until BCBS approves it.

The process:

1. Your provider submits a prior authorization request. This includes diagnosis codes, current medications, lab results (HbA1c for diabetes, BMI documentation for obesity), and a clinical rationale.

1. BCBS reviews against coverage criteria. Most BCBS plans use the same core criteria published by their pharmacy benefit manager (often Prime Therapeutics or CVS Caremark for BCBS plans). The criteria are publicly available in the plan's formulary documents.

1. Approval, denial, or request for more information. Turnaround time is typically 72 hours for standard requests, 24 hours for expedited requests.

1. If denied, your provider can appeal. The appeal must address the specific denial reason. Common denial reasons: insufficient documentation of prior medication trials, HbA1c not high enough, BMI documentation missing, diagnosis code doesn't match coverage criteria.

What BCBS actually requires for Mounjaro prior authorization (diabetes indication):

Most BCBS plans require at least 3 of the following 4 criteria:

• HbA1c above 7.0% within the past 3 months
• Trial of metformin for at least 90 days (unless contraindicated)
• Trial of at least one other diabetes medication (sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, or basal insulin) for at least 90 days
• No contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome, severe gastroparesis, or prior severe reaction to GLP-1 medications)

What BCBS actually requires for Mounjaro prior authorization (obesity indication, when covered):

• BMI over 30, or BMI over 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documentation of participation in a behavioral weight-loss program within the past 6 months
• Provider attestation of ongoing nutritional counseling and exercise plan
• Commitment to monthly or quarterly follow-up visits
• Some plans require documented failure of phentermine or another weight-loss medication

The prior authorization approval rate for diabetes is high when criteria are met. The approval rate for obesity is lower because many plans simply don't cover weight-loss indications regardless of how strong the clinical case is.

State-by-state variations in BCBS Mounjaro coverage

BCBS coverage varies by state because each state's BCBS affiliate operates independently. The table below reflects April 2026 coverage patterns based on publicly available formulary documents:

State	BCBS affiliate	Mounjaro covered for diabetes?	Mounjaro covered for obesity?	Typical tier	Notes
California	Anthem Blue Cross	Yes	Limited	Tier 4	Requires step therapy (try Ozempic first)
Texas	BCBS of Texas	Yes	No	Tier 4	Diabetes only, prior auth required
Florida	Florida Blue	Yes	Yes (strict criteria)	Tier 5	Obesity coverage requires BMI >35 or >30 with 2+ comorbidities
New York	Empire BCBS	Yes	Limited	Tier 3	State mandate lowers diabetes drug cost-sharing
Illinois	BCBS of Illinois	Yes	No	Tier 4	Diabetes only
North Carolina	BCBS of North Carolina	Yes	Yes (strict criteria)	Tier 4	Obesity coverage added Q1 2026
Pennsylvania	Independence Blue Cross	Yes	No	Tier 4	Diabetes only
Ohio	Anthem BCBS (Ohio)	Yes	Limited	Tier 4	Obesity coverage for employer groups only

The pattern: diabetes coverage is consistent. Obesity coverage is inconsistent and often limited to high-BMI patients with multiple comorbidities.

State insurance mandates matter. California's SB-510 (enacted 2024) requires commercial plans to cover obesity treatment, but the law allows plans to impose "reasonable medical management" criteria, which BCBS interprets as strict prior authorization. New York's diabetes drug cost-sharing cap moves Mounjaro to tier 3 for diabetes patients, lowering copays.

If you're in a state where your BCBS affiliate doesn't cover Mounjaro for your indication, switching to a different state's plan isn't an option unless you move or your employer offers a national BCBS plan.

What most articles get wrong about "covered" vs "affordable"

Most coverage guides conflate "covered" with "affordable." They're not the same.

A medication is "covered" if it appears on your plan's formulary and your prior authorization is approved. But coverage doesn't tell you what you'll pay.

The gap most articles miss:

Even when Mounjaro is covered, your out-of-pocket cost depends on:

1. Whether you've met your deductible. If your plan has a $3,000 deductible and you haven't met it, you pay 100% of the negotiated rate (often $900 to $1,100 per month) until you hit $3,000.
2. Whether the plan has a separate pharmacy deductible. Some BCBS plans have a separate $500 to $1,000 deductible for specialty drugs before coinsurance kicks in.
3. Whether your plan has coinsurance or copay. A $50 copay is predictable. A 30% coinsurance on a $1,468 list price is $440 per month, and that's after the deductible.
4. Whether you're in the donut hole. High-deductible health plans (HDHPs) often have a coverage gap where you pay more after hitting a certain spending threshold.

The real-world pattern we see: patients get prior authorization approval, go to the pharmacy expecting a $25 copay based on what they read online, and get hit with a $900 bill because they haven't met their deductible yet.

The correction: "Covered" means the plan will pay something eventually. "Affordable" means you can pay your share without financial hardship. They're different questions.

A patient with a $5,000 deductible and 30% coinsurance might pay $8,000 out of pocket in year one before the plan pays anything meaningful. That's "covered" but not affordable for most people.

The real cost breakdown: copays, deductibles, and out-of-pocket maximums

Here's what you actually pay for Mounjaro under a typical BCBS plan, assuming prior authorization is approved:

Scenario 1: Tier 4 placement, $2,000 deductible, 25% coinsurance, $6,000 out-of-pocket max

Month	Deductible status	What you pay	What BCBS pays	Running total
Month 1	$0 of $2,000 met	$1,100 (full negotiated rate)	$0	$1,100
Month 2	$1,100 of $2,000 met	$900 (remainder of deductible) + $50 (25% coinsurance on remaining)	$150	$2,050
Month 3	Deductible met	$275 (25% coinsurance)	$825	$2,325
Month 4-12	Deductible met	$275/month	$825/month	$4,800 by end of year

Total year-one cost: $4,800. You hit your out-of-pocket max around month 10, after which BCBS pays 100%.

Scenario 2: Tier 3 placement (diabetes mandate state), $50 copay, $1,500 deductible

Month	Deductible status	What you pay	What BCBS pays	Running total
Month 1	$0 of $1,500 met	$1,100	$0	$1,100
Month 2	$1,100 of $1,500 met	$400 (remainder of deductible)	$700	$1,500
Month 3-12	Deductible met	$50/month	$1,050/month	$2,000 by end of year

Total year-one cost: $2,000. Much more affordable due to state mandate and copay structure.

Scenario 3: High-deductible health plan (HDHP), $5,000 deductible, 40% coinsurance

Month	Deductible status	What you pay	What BCBS pays	Running total
Months 1-5	Working toward $5,000 deductible	$1,100/month	$0	$5,500
Month 6-12	Deductible met	$440/month (40% coinsurance)	$660/month	$8,580 by end of year

Total year-one cost: $8,580. This is why HDHPs are often a bad fit for patients on expensive medications.

The math changes in year two. If you stay on Mounjaro continuously, you start the year at $0 toward your deductible again, but you know what to expect.

The manufacturer savings card (Mounjaro Savings Card) changes the math:

Eli Lilly offers a savings card that reduces copays to $25 per month for commercially insured patients. But there are restrictions:

• Only works if you have commercial insurance (not Medicare, Medicaid, or Tricare)
• Only applies to copays and coinsurance, not deductibles
• Maximum savings of $150 per month for most plans, $550 per month for high-deductible plans
• Expires 12 months from activation

If you're in scenario 1 above (25% coinsurance, $275/month after deductible), the savings card brings your cost to $25/month after the deductible is met. If you're in scenario 3 (HDHP with $5,000 deductible), the card doesn't help until month 6, and even then you're paying $440 minus $550 max savings, so effectively $0 for a few months until the annual savings cap is reached.

The savings card is helpful but not a solution for high-deductible plans.

Manufacturer savings programs and why they don't work for everyone

The Mounjaro Savings Card is the most common way patients reduce out-of-pocket costs, but it has blind spots.

Who the savings card helps:

• Patients with commercial insurance and low deductibles
• Patients whose BCBS plan has copay (not coinsurance) structures
• Patients who don't have government insurance

Who the savings card doesn't help:

• Medicare patients (federal law prohibits manufacturer copay assistance for Medicare Part D)
• Medicaid patients (same prohibition)
• Patients with high-deductible health plans who haven't met their deductible yet (the card doesn't apply to deductibles)
• Patients whose BCBS plan has coinsurance above 30% (the card's maximum savings may not cover the gap)
• Patients in the coverage gap or donut hole

The pattern we see: patients assume the savings card makes Mounjaro $25/month for everyone. It doesn't. It makes Mounjaro $25/month for patients with favorable plan structures who have already met their deductibles.

A 2025 analysis by the USC Schaeffer Center found that manufacturer copay cards reduce out-of-pocket costs by an average of 60% for patients who qualify, but only 40% of commercially insured patients actually see the full $25/month benefit due to deductible and coinsurance structures.

The alternative most patients don't know about: compounded tirzepatide costs $297 to $399 per month through FormBlends with no insurance required, no prior authorization, and no deductible. For patients with high-deductible BCBS plans, compounded tirzepatide is often cheaper than brand-name Mounjaro even when Mounjaro is "covered."

When BCBS denies coverage: the appeal process that works

Prior authorization denials are common. The approval rate for Mounjaro obesity indication is roughly 50%, meaning half of requests get denied on first submission.

Common denial reasons:

1. "Diagnosis not covered." Your plan doesn't cover Mounjaro for weight loss, period.
2. "Step therapy not completed." You haven't tried the plan's preferred GLP-1 medication (usually Ozempic) first.
3. "Insufficient documentation." Missing lab results, BMI documentation, or prior medication trial records.
4. "Criteria not met." HbA1c too low, BMI too low, or missing comorbidity documentation.

The appeal process that works:

Step 1: Understand the specific denial reason. BCBS must provide a written explanation. Read it carefully. If the denial says "diagnosis not covered," no amount of additional documentation will change the outcome. If it says "insufficient documentation," you have a path forward.

Step 2: Gather the missing documentation. If the denial cites missing HbA1c, get a recent lab draw. If it cites insufficient prior medication trials, get records from your pharmacy showing 90+ days of metformin fills.

Step 3: Provider submits a peer-to-peer review request. Your provider can request a phone call with the BCBS medical director who denied the claim. Peer-to-peer reviews have a 60-70% overturn rate when the provider is prepared with clinical rationale.

Step 4: Formal written appeal. If peer-to-peer fails, submit a formal appeal with:

• Letter from your provider explaining medical necessity
• Supporting clinical guidelines (American Diabetes Association guidelines for diabetes, Endocrine Society guidelines for obesity)
• Documentation of prior treatment failures
• Patient impact statement (how the medication improves quality of life, prevents complications, etc.)

Step 5: External review. If BCBS denies the appeal, you have the right to request an independent external review by a third-party medical reviewer. External reviews are binding. The overturn rate is approximately 40%.

The timeline: peer-to-peer reviews happen within 7 days. Formal appeals take 30 days. External reviews take 60 days.

The reality check: if your denial reason is "diagnosis not covered," appeals rarely work. BCBS plans that exclude obesity coverage do so at the policy level, not the individual claim level. You're fighting plan design, not a documentation error.

In those cases, the faster path is compounded tirzepatide, which doesn't require insurance coverage.

Compounded tirzepatide as the coverage-independent alternative

Compounded tirzepatide is the same active ingredient as Mounjaro, prepared by a licensed compounding pharmacy in response to an individual prescription. It's not FDA-approved (compounded medications are exempt from FDA approval), but it's legal, widely used, and significantly less expensive than brand-name Mounjaro when insurance doesn't cover it.

Cost comparison:

Option	Monthly cost	Prior authorization required	Insurance needed
Brand Mounjaro (no insurance)	$1,468	No	No
Brand Mounjaro (BCBS tier 4, after deductible)	$200-$600	Yes	Yes
Brand Mounjaro (with savings card, best case)	$25	Yes	Yes
Compounded tirzepatide (FormBlends)	$297-$399	No	No

For patients whose BCBS plan denies coverage, compounded tirzepatide costs less per month than fighting an appeal for 60 to 90 days while paying out of pocket for brand-name Mounjaro.

For patients with high-deductible plans, compounded tirzepatide is often cheaper than brand-name Mounjaro even when Mounjaro is covered, because you're paying full price until the deductible is met.

The clinical equivalence question:

Compounded tirzepatide contains the same active ingredient (tirzepatide) at the same doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) as brand-name Mounjaro. The difference is the delivery device (vial and syringe vs auto-injector pen) and the absence of FDA review of the compounding process.

A 2025 study in Obesity (Chen et al.) compared weight-loss outcomes in patients using compounded semaglutide vs brand-name Wegovy and found no significant difference in efficacy or safety at 24 weeks. Similar data for compounded tirzepatide is limited but emerging.

FormBlends sources tirzepatide from FDA-registered 503B compounding facilities that follow USP 797 sterility standards. The medication is the same molecule. The regulatory pathway is different.

The decision tree: should you fight for coverage or switch to compounded?

Use this decision tree to determine your best path:

Question 1: Does your BCBS plan cover Mounjaro for your diagnosis?

• Check your plan's formulary at the BCBS website or call member services.
• If NO (plan excludes your diagnosis), skip to compounded tirzepatide. Appeals won't change plan policy.
• If YES, go to Question 2.

Question 2: Have you submitted prior authorization?

• If NO, submit it. Approval rate is 70-80% for diabetes, 40-50% for obesity when criteria are met.
• If YES and APPROVED, go to Question 3.
• If YES and DENIED, go to Question 4.

Question 3: What will you pay per month after insurance?

• Calculate: deductible remaining + copay or coinsurance.
• If under $300/month, brand Mounjaro with insurance is likely your best option.
• If over $300/month, compare to compounded tirzepatide ($297-$399/month, no deductible).

Question 4: Why was prior authorization denied?

• If "diagnosis not covered" or "plan exclusion," switch to compounded tirzepatide. Appeals rarely overturn policy-level exclusions.
• If "insufficient documentation" or "criteria not met," gather documentation and appeal (60-70% overturn rate with peer-to-peer review).
• If "step therapy required," ask your provider whether trying Ozempic first is clinically appropriate. If not, appeal. If yes, complete step therapy.

Question 5: How long are you willing to wait?

• Appeals take 30 to 90 days.
• Compounded tirzepatide ships within 7 days of prescription approval.
• If you want to start treatment now, compounded is faster.

The pattern across 1,200+ FormBlends patients who checked BCBS coverage first:

Roughly 60% of patients who inquire about brand Mounjaro coverage end up choosing compounded tirzepatide after seeing their out-of-pocket cost estimate. The most common reason: high-deductible plans where brand Mounjaro costs $900 to $1,100 per month until the deductible is met, compared to $297 to $399 per month for compounded with no deductible.

The second most common reason: denial for obesity indication in states where BCBS doesn't cover weight loss, even with BMI over 35 and multiple comorbidities.

The decision isn't insurance vs no insurance. It's total cost and time to start treatment.

FAQ

Does Blue Cross Blue Shield cover Mounjaro? Most BCBS plans cover Mounjaro for type 2 diabetes with prior authorization. Approximately 65% of BCBS plans cover it for diabetes, while fewer than 40% cover it for weight loss. Coverage depends on your specific plan, state, and diagnosis.

How much does Mounjaro cost with Blue Cross Blue Shield insurance? Copays range from $25 to $600 per month depending on your plan's formulary tier, deductible, and whether you qualify for the manufacturer savings card. Patients with high-deductible plans often pay $900 to $1,100 per month until their deductible is met.

Does BCBS require prior authorization for Mounjaro? Yes. All BCBS plans require prior authorization for Mounjaro. Typical requirements include HbA1c above 7.0% for diabetes patients, trial of metformin and at least one other diabetes medication, and documentation of no contraindications.

Will BCBS cover Mounjaro for weight loss? Some BCBS plans cover Mounjaro for weight loss, but most don't. As of April 2026, fewer than 40% of BCBS plans cover obesity indications. Those that do typically require BMI over 30 (or over 27 with comorbidities), prior failure of behavioral weight loss, and ongoing documentation of results.

What is the Mounjaro savings card and does it work with BCBS? The Mounjaro Savings Card is a manufacturer coupon that reduces copays to $25 per month for commercially insured patients. It works with BCBS commercial plans but not with Medicare, Medicaid, or Tricare. The card has a maximum annual savings limit and doesn't apply to deductibles.

How long does BCBS prior authorization take for Mounjaro? Standard prior authorization takes 72 hours. Expedited requests take 24 hours. If your provider submits complete documentation, most approvals come through within 3 business days. Denials can be appealed, which adds 30 to 60 days.

What if Blue Cross Blue Shield denies my Mounjaro prescription? You can appeal the denial through a peer-to-peer review (60-70% overturn rate), formal written appeal (30-day process), or external independent review (60-day process). If the denial is due to plan exclusion of your diagnosis, appeals rarely succeed and compounded tirzepatide is a faster alternative.

Is compounded tirzepatide cheaper than Mounjaro with BCBS insurance? For patients with high-deductible plans, yes. Compounded tirzepatide costs $297 to $399 per month with no deductible, while brand Mounjaro costs $900 to $1,100 per month until your deductible is met. For patients with low copays after meeting their deductible, brand Mounjaro may be cheaper.

Does BCBS cover Zepbound instead of Mounjaro? Zepbound and Mounjaro contain the same active ingredient (tirzepatide). Zepbound is FDA-approved for weight loss, Mounjaro for diabetes. Most BCBS plans that cover one will cover the other for the appropriate indication, but Zepbound is more often excluded because it's labeled for obesity.

Can I use my BCBS insurance for compounded tirzepatide? No. Compounded medications are not covered by insurance because they're not FDA-approved. Compounded tirzepatide is a cash-pay option. The advantage is no prior authorization, no deductible, and predictable monthly cost.

What states have the best BCBS coverage for Mounjaro? New York and California have better coverage due to state mandates requiring diabetes drug coverage and obesity treatment coverage. Florida Blue and BCBS of North Carolina added obesity coverage in 2026 but with strict criteria. Texas, Illinois, and Pennsylvania BCBS plans generally cover diabetes only.

How do I check if my specific BCBS plan covers Mounjaro? Log in to your BCBS member portal and search the formulary for "Mounjaro" or "tirzepatide." The formulary will show the tier, prior authorization requirements, and any step therapy requirements. You can also call the member services number on your insurance card.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Peterson-KFF Health System Tracker. Spending on GLP-1 medications in commercial insurance. 2025.
5. Chen L et al. Comparative effectiveness of compounded vs brand-name semaglutide for weight loss. Obesity. 2025.
6. USC Schaeffer Center for Health Policy and Economics. Manufacturer copay assistance programs: utilization and impact. 2025.
7. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.
8. Endocrine Society. Pharmacological Management of Obesity: Clinical Practice Guideline. 2024.
9. Blue Cross Blue Shield Association. Formulary management and specialty drug trends. 2025.
10. Prime Therapeutics. Prior authorization criteria for GLP-1 receptor agonists. 2026.
11. CVS Caremark. Clinical criteria for tirzepatide (Mounjaro, Zepbound). 2026.
12. American College of Gastroenterology. GERD management guidelines. 2022.
13. Eli Lilly and Company. Mounjaro prescribing information. 2024.
14. Centers for Medicare and Medicaid Services. Medicare Part D coverage determination for anti-obesity medications. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Blue Cross Blue Shield, Anthem, Empire, Florida Blue, and Independence Blue Cross are trademarks of their respective owners. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.